The evolution of the treatment landscape for NSCLC marks a shift in precision medicine. Historically, platinum-based doublets were chosen for every patient. Now during diagnosis, all patients with metastatic NSCLC should undergo molecular testing measuring EGFR, ALK, ROS1, PD-L1, NRTK, BRAF, and KRAS codon 12 to help determine whether a tyrosine kinase inhibitor (TKI) should be used in place of cytotoxic chemotherapy.
Although pathways of oncogenic addiction have been characterized the most in lung cancer, researchers have also made strides in providing personalized medicine in the areas of colorectal cancer, breast cancer, leukemia, lymphoma, melanoma, esophageal cancer, stomach cancer, ovarian cancer, and thyroid cancer.
Learn more about genetic testing to select targeted therapies for patients with NSCLC.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan. Fast Five Quiz: Precision Medicine in Cancer - Medscape - Jul 15, 2021.
Comments